Replies to post #69967 on Biotech Values

[ghmm]

EPIX:

Just announced Vasovist approval. Now, lets see if it is the first one knocked off this list. EPIX isn't going to do anything with it on their own!

[DewDiligence]

Quiz: Why isn’t SGP’s TRA antiplatelet drug on the list, given that Fred Hassan has stated on numerous occasions that the phase-3 clinical program for TRA is too expensive for SGP to pursue on its own?

[genisi]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program is in phase-3 or beyond and is non-partnered.
b) Company does not have enough cash to bring the product to market.

Edits: Added - CRGB, INFI, OREX, SVNT; Removed - LJPC

  
  
  Stock    Product          Stage                   Comments       
  -----    ---------------  ---------------------   -----------------------------       
  AEZS     Cetrorelix       Phase 3                 BPH Q3 '09 Efficacy results due.  
  AUXL     Xiaflex          Phase 3                 Dupuytren's Contracture (and PH2 for peyronie's and frozen shoulder syndrome)   
  BPAX     Libigel          Phase 3 ~2010 Submit    Adequate Safety?       
  CHTP     Droxidopa        Pivotal Phase III       Orthostatic hypotension.  Results expected 02/09. 
  CRGB     Abiraterone      Phase 3                 Prostate cancer 
  DYAX     DX-88 for HAE    BLA filed 9/24/08       (CABG indication partnered w CBST)    
  EPIX     Vasovist         PDUFA 12/30/08          FDA initially rejected saying 2 more studies needed. Looking to sell outright on approval.    
  GNVC     TNFerade         Pivotal Phase III       Pancreatic cancer 
  INFI     Retaspimycin     Phase 3                 GI stromal tumors  
  JAV      Dyloject         Phase III               Approved in UK.  Post operative Pain (injectable)     
  JAV      Ketamine         Phase III               Acute moderate-to-severe pain (intranasal)  
  NTII     Viprinex         Phase 3                 Interim analysis January '09.  Stroke Drug, high chance of failure.       
  OREX     Contrave         Phase 3                 Obesity 
  OXGN     Zybrestat        Phase 3                 Anaplastic thyroid cancer    
  Pharming Rhucin           Pre-BLA                 Rejected in EU  
  Protalix prGCD            Phase III               Gaucher's disease. Not enough cash for a commercial infrastructure   
  RPRX     Proellex         Phase 3                 Uterine fibroids 
  SVNT     Puricase         BLA filed               Treatment refratory gout  
   
   
  

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.

[ghmm]

Late-Stage Products Looking for a Home

We have one off the list!

BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent

http://finance.yahoo.com/news/BioMarin-and-La-Jolla-prnews-13982889.html